ArticleTranslational oncology2026
Overexpression of NMNAT3 suppresses melanoma progression by reprogramming NAD⁺ metabolism.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reading the tumour at single-cell resolution: Original research in the Precision Therapeutics special issue.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma represents a highly aggressive and metastatic form of malignant skin cancer. that remains challenging to treat clinically. Tumor cells often reprogram nicotinamide adenine dinucleotide (NAD⁺) metabolism to meet the demands of rapid proliferation and metastasis, however, its function and mechanism in melanoma remain unclear. MATERIALS AND
methodsKey NAD⁺ metabolism-related genes associated with melanoma were screened using bioinformatic analysis of public databases (GEO and TCGA). Weighted Gene Co-expression Network Analysis (WGCNA) and machine learning approaches, further pinpointed NMNAT3 as a critical target for subsequent research. Confirmation of NMNAT3 expression on A375 melanoma cell line by qRT-PCR. Functional assays, including CCK-8 for proliferation, scratch wound for migration, and transwell for invasion, were employed to determine the roles of NMNAT3 in melanoma cells. Furthermore, an immune cell infiltration analysis was conducted to examine the association of NMNAT3 expression with the tumor immune microenvironment.
resultsBioinformatic analyses indicated a downregulation of NMNAT3 in melanoma tissues and cell lines, demonstrating significant diagnostic potential. Moreover, Immunoanalysis shows important links between NMNAT3 expression and invasive levels of various immunologic types within the melanoma tumour microenvironment. Subsequent in vitro functional studies further showed that that NMNAT3 overexpression can significantly inhibit the malignant phenotype of melanoma cells.
conclusionsThis study is the first to reveal the inhibitory role of NMNAT3 in melanoma growth. This study ensures an understanding of the theoretical principles of melanoma metabolic regulation and NMNAT3 treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.